Abstract:Background: Efficacy and safety of upadacitinib (UPA) 15 mg (UPA15) once daily (QD) and UPA 30 mg QD (UPA30) maintenance therapy in patients with Crohn’s disease (CD) were evaluated in U-ENDURE. Methods: Patients with moderate to severe CD who responded (≥30% decrease average daily very soft/liquid stool frequency [SF] and/or average daily abdominal pain score [APS], neither greater than baseline) to 12-weeks (wks) of UPA 45 mg QD induction therapy were eligible for U-ENDURE. At wk0, patients were randomized (1:1:1) to receive UPA15, UPA30 or placebo (PBO) as maintenance therapy for 52 wks1. Co-primary endpoints, clinical remission per CD activity index (CDAI) or SF/APS and endoscopic response, were evaluated at wk52. Other efficacy and safety outcomes were evaluated at or through wk52. Results: At wk52, greater proportion of patients receiving UPA15 (n = 169) and UPA30 (n = 168) vs PBO (n = 165) achieved clinical remission per CDAI (37.3% [95%CI: 30.0%, 44.6%] and 47.6% [40.1%, 55.2%] vs 15.1% [9.6%, 20.6%]) and SF/APS (35.5% [28.3%, 42.7%] and 46.4% [38.9%,54.0%] vs 14.4% [9.0%,19.8%]) (all P < 0.0001 vs PBO for both doses). UPA15 and UPA30 patients attained greater rates of endoscopic response vs PBO (27.6% [95%CI: 20.8%, 34.4%] and 40.1% [32.7%, 47.6%] vs 7.3% [3.3%, 11.2%]; P < 0.0001 vs PBO for both doses). UPA15 and UPA30 were superior vs PBO for key secondary endpoints at wk52 including clinical response (41.4% and 51.2% vs 15.2%), endoscopic remission (19.1% and 28.6% vs 5.5%), maintenance of clinical remission (per CDAI: 49.5% and 65.2% vs 21.2%; per SF/APS: 50.5% and 60.0% vs 19.6%), corticosteroid-free clinical remission in all patients (per CDAI, 36.7% and 46.4% vs 14.5%; per SF/APS, 34.9% and 44.6% vs 14.4%) and in patients with baseline steroid use (per CDAI, 39.7% and 39.7% vs 4.9%; per SF/APS, 38.1% and 38.1% vs 4.9%), clinical+endoscopic remission (per CDAI, 14.8% and 23.2% vs 3.7%; per SF/APS, 13.7% and 22.6% vs 4.3%), and change from baseline in IBDQ total score (LS mean[SE]: 59.3[3.22] and 64.5[3.15] vs 46.4[4.02]) (all P < 0.01 vs PBO for both doses). UPA30-treated patients also demonstrated significant improvement from baseline in FACIT-F vs PBO (LS mean[SE]: 16.1[1.02] vs 12.0[1.34]; P < 0.001). Rates of adverse events (AE) and serious AEs were similar across UPA groups; AE leading to treatment discontinuation rates were similar across groups. Most common AE was CD worsening (UPA15: 29.7 events/100 patient-years [E/100PY], UPA30: 12.0E/100PY, PBO: 58.0E/100PY). Serious infection rates were similar across groups (6.1-8.4 E/100PY); herpes zoster rate was higher in UPA30 (7.2E/100PY) vs PBO (4.7E/100PY) and UPA15 (4.0E/100PY). Malignancies excluding non-melanoma skin cancer (NMSC) were reported in 1 UPA15 patient and 2 UPA30 patients; all events were diagnosed within 9 months of first UPA exposure. One gastrointestinal perforation was reported in each group. One event of hepatic vein thrombosis was reported in UPA30. No deaths, tuberculosis, NMSC, or adjudicated cardiovascular events occurred in any group. Conclusion(s): Among patients with moderate to severe active CD who respond to UPA induction therapy, UPA15 and UPA30 maintenance treatments were well tolerated and superior to PBO for all clinical and endoscopic outcomes, and most quality-of-life outcomes at wk52.

Impact of Adalimumab (HUMIRA®) on Patient-Reported Outcomes among Patients with Fistulizing Crohnʼs Disease in the CHARM Trial

Continuous Vs. Induction Only/Reinitiated Adalimumab Maintenance Therapy Yields Optimal Results for Moderate to Severe Crohnʼs Disease: Subanalysis of CHARM

Efficacy and safety of adalimumab in the treatment of Crohn′s disease

Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn's Perianal Fistulae

Adalimumab Maintenance Therapy for Patients with Crohnʼs Disease is Cost Effective Compared with Nonbiologic Maintenance Therapy

Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials

Distinct Alterations of Fecal Microbiota Refer to the Efficacy of Adalimumab in Crohn’s Disease

Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study

Infliximab maintenance therapy for fistulizing Crohn's disease.

Adalimumab - an effective and promising treatment for patients with fistulizing Crohn's disease: a case series

P337 Proactive therapeutic drug monitoring of Adalimumab, but not HLADQ*A1 determination, predicts inflammatory bowel disease outcome and persistence of treatment

The Choice Trial: Adalimumab Demonstrates Safety, Fistula Healing, Improved Quality of Life and Increased Work Productivity in Patients with Crohn'S Disease Who Failed Prior Infliximab Therapy

P870 Effectiveness and safety of adalimumab as first line biological treatment in Ulcerative Colitis

S37 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results

INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn’s Disease Treated in the ADMIRE-CD Trial

P874 Impact of immunogenicity on clinical outcomes in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study

Infliximab for Crohn’s Disease Patients with Perianal Fistulas: Better Image, Better Life

P700 The efficacy of adalimumab combined with surgery for rectovaginal fistula in Crohn's disease:a single-center retrospective study

P-107 Adalimumab Therapy Achieves Clinical Remission and Response at Week 26 in Chinese Patients with Crohnʼs Disease

P851 Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel Disease

P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn’s disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies